Insider Trading Alert - INTU, JAZZ And STNR Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Nov. 25, 2014, 127 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $158.00 to $38,255,692.50.

Highlighted Stocks Traded by Insiders:

Intuit (INTU) - FREE Research Report

Smith Brad D, who is President, CEO and Director at Intuit, sold 116,005 shares at $92.41 on Nov. 25, 2014. Following this transaction, the President, CEO and Director owned 123,377 shares meaning that the stake was reduced by 48.46% with the 116,005-share transaction.

The shares most recently traded at $92.70, up $0.29, or 0.32% since the insider transaction. Historical insider transactions for Intuit go as follows:

  • 4-Week # shares sold: 20,000
  • 12-Week # shares sold: 43,724
  • 24-Week # shares sold: 72,520

The average volume for Intuit has been 1.6 million shares per day over the past 30 days. Intuit has a market cap of $26.5 billion and is part of the technology sector and computer software & services industry. Shares are up 21.41% year-to-date as of the close of trading on Tuesday.

Intuit Inc. provides business and financial management solutions for small businesses, consumers, and accounting professionals in the United States, Canada, the United Kingdom, Australia, India, and Singapore. The stock currently has a dividend yield of 1.08%. The company has a P/E ratio of 32.3. Currently, there are 7 analysts who rate Intuit a buy, 1 analyst rates it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on INTU - FREE

TheStreet Quant Ratings rates Intuit as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Intuit Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Jazz Pharmaceuticals (JAZZ) - FREE Research Report

Tobias Jeffrey K, who is EVP, Research & Dev and CMO at Jazz Pharmaceuticals, sold 4,598 shares at $170.12 on Nov. 25, 2014. Following this transaction, the EVP, Research & Dev and CMO owned 34,940 shares meaning that the stake was reduced by 11.63% with the 4,598-share transaction.

The shares most recently traded at $173.99, up $3.87, or 2.22% since the insider transaction. Historical insider transactions for Jazz Pharmaceuticals go as follows:

  • 4-Week # shares sold: 9,181
  • 12-Week # shares sold: 123,551
  • 24-Week # shares sold: 201,565

The average volume for Jazz Pharmaceuticals has been 820,100 shares per day over the past 30 days. Jazz Pharmaceuticals has a market cap of $10.3 billion and is part of the health care sector and drugs industry. Shares are up 34.66% year-to-date as of the close of trading on Tuesday.

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a P/E ratio of 340.9. Currently, there are 10 analysts who rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on JAZZ - FREE

TheStreet Quant Ratings rates Jazz Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and premium valuation. Get the full Jazz Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Steiner Leisure (STNR) - FREE Research Report

Boehm Robert C, who is Exec. V.P. & General Counsel at Steiner Leisure, sold 2,616 shares at $44.00 on Nov. 25, 2014. Following this transaction, the Exec. V.P. & General Counsel owned 27,048 shares meaning that the stake was reduced by 8.82% with the 2,616-share transaction.

The shares most recently traded at $42.97, down $1.03, or 2.41% since the insider transaction. Historical insider transactions for Steiner Leisure go as follows:

  • 4-Week # shares sold: 19,816
  • 12-Week # shares sold: 31,805
  • 24-Week # shares sold: 40,306

The average volume for Steiner Leisure has been 59,000 shares per day over the past 30 days. Steiner Leisure has a market cap of $590.0 million and is part of the services sector and diversified services industry. Shares are down 11.99% year-to-date as of the close of trading on Tuesday.

Steiner Leisure Limited provides spa services and personal care products for men, women, and teenagers worldwide. The company operates in four segments: Spa Operations, Products, Schools, and Laser Hair Removal. The company has a P/E ratio of 15.5. Currently, there are 3 analysts who rate Steiner Leisure a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on STNR - FREE

TheStreet Quant Ratings rates Steiner Leisure as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth and increase in net income. However, as a counter to these strengths, we also find weaknesses including poor profit margins, a generally disappointing performance in the stock itself and feeble growth in the company's earnings per share. Get the full Steiner Leisure Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

In Trump Era, Managing JPMorgan Is As Unpredictable As a Midnight Tweet

In Trump Era, Managing JPMorgan Is As Unpredictable As a Midnight Tweet

Video: Don't Underestimate China's Strength in a Trade War

Video: Don't Underestimate China's Strength in a Trade War

Master Limited Partnerships: A Badly Missed Investment Opportunity?

Master Limited Partnerships: A Badly Missed Investment Opportunity?

America's Massive Truck Driver Shortage May Triple by 2026: Experts

America's Massive Truck Driver Shortage May Triple by 2026: Experts

Top Analysts Say Gamble On These 3 Ace Stocks

Top Analysts Say Gamble On These 3 Ace Stocks